Novel, Sensitive, Digital Endpoints that Detect ALS Progression for Clinical Studies: Early Data from Pretreatment Run-In Period in Proof-of-Concept ALS Study VGCS-50635-002

Time: 1:00 pm
day: Conference Day One Track B PM

Details:

  • The ALS-FRS-R is the primary efficacy endpoint for proof of concept and registrational ALS trials
  • It is challenging to perform early efficacy (Proof of Concept) and dose ranging studies in ALS with the ALS-FRS-R as large sample size and long study duration is needed
  • Digital clinical biomarkers could provide a better option for Proof of Concept, dose-ranging studies than the ALSFRS-R due to better precision, lower variability, and better measurement properties

Speakers:

Anil Tarachandani
Anil Tarachandani